Latest News

Clinical study suggests efficacy of modafinil to improve memory in patients with depression

Clinical study suggests efficacy of modafinil to improve memory in patients with depression

Sanaria reports positive results from Phase II trial of PfSPZ Vaccine for malaria

Sanaria reports positive results from Phase II trial of PfSPZ Vaccine for malaria

CalciMedica begins Phase I trials for CRAC channel inhibitor

US-based bio-pharmaceutical company CalciMedica has initiated the Phase I safety studies in healthy volunteers of a new calcium release-activated calcium (CRAC) channel inhibitor, CM4620,...

CalciMedica begins Phase I trials for CRAC channel inhibitor

M&As this week: Shenzhen Neptunus Bioengineering, Korea Value Asset Management, Catalent

Shenzhen Neptunus Bioengineering plans to acquire a 70% stake in a pharmaceutical company based in Hunan,...

M&As this week: Shenzhen Neptunus Bioengineering, Korea Value Asset Management, Catalent

Deals this week: Teva Pharma, Boston Children’s Hospital, MedImmune

Teva Pharma Industries and Syqe Medical have entered an agreement to market medical cannabis inhalers in...

Deals this week: Teva Pharma, Boston Children’s Hospital, MedImmune

NIAID-funded clinical trial to evaluate shorter-duration antibiotics in children

Five medical centres in the US are planning to conduct the SCOUT-CAP clinical trial to determine the efficacy of shorter course of antibiotics in treating community-acquired pneumonia (CAP)...

NIAID-funded clinical trial to evaluate shorter-duration antibiotics in children

NIAID to begin HVTN 702 study of new HIV vaccine regimen in South Africa

NIAID to begin HVTN 702 study of new HIV vaccine regimen in South Africa

M&As this week: Allergen, Primex Pharmaceuticals, Cheisi Farmaceutici

Allergen has acquired Chase Pharmaceuticals Corporation from New Rhein Healthcare Investors for a purchase consideration of...

M&As this week: Allergen, Primex Pharmaceuticals, Cheisi Farmaceutici

Deals this week: Rosetta Genomics, Enamine, Wuxi Biologics

Rosetta Genomics and Sheba Medical Centre have entered a research agreement to develop and evaluate the efficacy of microRNA biomarkers to analyse the response of the drug nivolumab in lung...

Deals this week: Rosetta Genomics, Enamine, Wuxi Biologics

Galapagos begins DIVERSITY Phase III study of filgotinib to treat Crohn’s disease

Belgium-based clinical-stage biotechnology company Galapagos has begun its DIVERSITY Phase III study of filgotinib to treat Crohn’s disease...

Galapagos begins DIVERSITY Phase III study of filgotinib to treat Crohn’s disease

Washington University and Harvard Medical School report positive topical immunotherapy trial results

Washington University and Harvard Medical School report positive topical immunotherapy trial results

Dermata Therapeutics commences treatment in Phase 2 atopic dermatitis study

Biotechnology company Dermata Therapeutics has announced the dosing of its first patient in a Phase 2 atopic dermatitis study with its lead compound DMT210. ...

Dermata Therapeutics commences treatment in Phase 2 atopic dermatitis study

M&As this week: Northsight Capital, GL Capital and ABG Management, Tonghua Golden Horse Pharmaceutical Industry

Northsight Capital plans to acquire Stargreen Holdings to expand its business and presence in the cannabis...

M&As this week: Northsight Capital, GL Capital and ABG Management, Tonghua Golden Horse Pharmaceutical Industry

Deals this week: Pfizer, Peakdale Molecular, Selexis

Pfizer and National Cancer Institute have entered a co-operative research and development (R&D) agreement to develop novel immunotherapy candidates targeting multiple...

Deals this week: Pfizer, Peakdale Molecular, Selexis

M&As this week: Sichuan Kelun Pharma, CiToxLAB

Sichuan Kelun Pharma has announced its intention to acquire stakes in two pharmaceutical companies, one based in Guangxi and another in...

M&As this week: Sichuan Kelun Pharma, CiToxLAB

Deals this week: GeoVax Labs, Yisheng Biopharma, Oryzon Genomics

GeoVax Labs and ViaMune have signed a co-development agreement for cancer immunotherapy...

Deals this week: GeoVax Labs, Yisheng Biopharma, Oryzon Genomics

M&As this week: Signal Genetics, Celldex Therapeutics

US-based molecular diagnostic company Signal Genetics is set to merge with clinical-stage biopharmaceutical company miRagen Therapeutics, with the boards of directors of both companies...

M&As this week: Signal Genetics, Celldex Therapeutics

Deals this week: miRagen Therapeutics, Zhongyuan Union Cell, Health Advance

US-based biopharmaceutical company miRagen Therapeutics plans to raise $40m through private placement of its common stock shares with the help of placement agent Wedbush...

Deals this week: miRagen Therapeutics, Zhongyuan Union Cell, Health Advance

M&As this week: I’rom Group, Walgreens Boots Alliance

I’rom Group Co plans to acquire a 61% stake in CMAX from IDT Australia for a purchase consideration of A$10m...

M&As this week: I’rom Group, Walgreens Boots Alliance

Deals this week: Kerecis, PharmaJet, Fimbrion Therapeutics

Kerecis and the US Department of Defence have entered an agreement to develop fish skin burn...

Deals this week: Kerecis, PharmaJet, Fimbrion Therapeutics

Report: Penetrating crowded heart failure market could prove difficult for Omecamtiv Mecarbil

Cytokinetics’ new heart failure drug, Omecamtiv Mecarbil (OM), will have to target patient subgroups in order to succeed in the crowded heart failure market, says GlobalData in its recent...

Report: Penetrating crowded heart failure market could prove difficult for Omecamtiv Mecarbil